Vactosertib and Durvalumab in Gastric Cancer
This trial will test the efficacy and safety of durvalumab in combination with vactosertib in patients with metastatic gastric cancers who failed ≥ 2 lines of chemotherapy
Stomach Neoplasm
DRUG: durvalumab and vactosertib
Objective response rate, Objective response rate in 55 participants according to RECIST v1.1, Every 8 weeks from the date of the first dose until the date of progression, assessed up to 1 year
Efficacy and safety of durvalumab (anti-PD-L1) via IV infusion Q4W, in combination with vactosertib (TGF-beta inhibitor) PO bid for 5 days a week for up to a maximum of 12 months, will be tested in patients with metastatic hypermutated gastric cancers as ≥ 3rd-line setting until confirmed disease progression, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.